Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).

Authors

Yun Chen

Fudan University Shanghai Cancer Center, Shanghai, China

Yun Chen , Jingjun Ye , Zhengfei Zhu , Weixin Zhao , Ling Li , Min Fan , Chaoyang Wu , Huarong Tang , Gang Xu , Qin Lin , Jiancheng Li , Yi Xia , Yunhai Li , Jialiang Zhou , Kuaile Zhao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.

First Author: Manabu Muto

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Final results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma.

First Author: Dashan Ai

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).

First Author: Dashan Ai

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).

First Author: Satoru Matsuda